US Patent 9,974,742: Scope, Claims, Expiration, Orange Book Status, and NK-1 Emulsion Patent Landscape

US Patent 9,974,742 protects injectable oil-in-water emulsions containing an NK-1 receptor antagonist, with defined emulsifier, oil, pH, and component-ratio requirements. Its strongest commercial relevance is to rolapitant injectable emulsion products, particularly Varubi injection. The patent also contains process claims covering preparation, microfluidization, sterile filtration, and post-emulsification addition of dexamethasone sodium phosphate.

The patent does not broadly cover every injectable NK-1 antagonist. A product must satisfy the claimed formulation architecture or the claimed manufacturing steps. Aprepitant is expressly excluded from dependent claims 15 and 23, although claim 1 itself does not contain that exclusion.

What does US Patent 9,974,742 protect?

US 9,974,742 contains two principal claim groups:

Composition claims 1-15, directed to injectable pharmaceutical emulsions.
Manufacturing claims 16-23, directed to preparation and sterilization of those emulsions.

The patent is assigned to Tesaro, Inc., which became part of GlaxoSmithKline through GSK's 2019 acquisition of Tesaro. The technology corresponds closely to the formulation used for intravenous rolapitant, marketed as Varubi injection.

Composition claim structure

Claim 1 requires all of the following:

Required element	Claim limitation
Dosage form	Injectable pharmaceutical emulsion
Active ingredient	NK-1 receptor antagonist
Emulsifier	11 wt/wt% to 15 wt/wt%
Oil	Required, but not specifically limited in claim 1
Co-surfactant	Must comprise an alcohol
Other components	Tonicity agent, pH modifier, and water
pH	About 7.5 to 9.0
Emulsifier-to-active ratio	About 18:1 to 22:1 by weight

The claim is formulation-specific. It does not cover an NK-1 antagonist merely because the active ingredient is administered by injection. The accused product must also contain the specified emulsion system and fall within the claimed pH and emulsifier-ratio ranges.

Dependent composition claims

Claims 2-14 narrow claim 1 through additional composition limits:

Claim	Added limitation	Commercial or technical significance
2	Oil-to-active ratio of about 5:1 to 15:1	Covers a broad oil-loading range
3	Oil-to-active ratio of about 10:1 to 15:1	Narrower preferred range
4	Emulsifier-to-oil ratio of about 1:1 to 3:1	Defines the relative lipid and emulsifier balance
5	Emulsifier is a phospholipid	Limits the emulsifier class
6	Emulsifier is egg lecithin	Closely aligned with commercial lipid emulsions
7	Dexamethasone sodium phosphate in the aqueous phase	Covers a combination product architecture
8	Specified NK-1 antagonists	Includes rolapitant, netupitant, ezlopitant, vestipitant, serlopitant, maropitant, casopitant, befetupitant, and orvepitant
9	pH modifier is oleic acid or a salt	Covers oleate-based pH adjustment
10	pH modifier is a buffer	Defines an alternative buffering approach
11	Buffer is Tris	Narrows the buffer embodiment
12	Oil is soybean oil	Covers the principal commercial soybean-oil embodiment
13	Alcohol is ethanol	Narrows the co-surfactant
14	Ethanol is below 10 wt/wt%	Adds a concentration ceiling
15	NK-1 antagonist is not aprepitant	Removes aprepitant from the dependent-claim scope

Claims 2 and 3 overlap. A formulation with an oil-to-active ratio of 10:1 to 15:1 falls within both ranges, assuming every limitation of claim 1 is satisfied.

Which drugs fall within the claimed NK-1 antagonist group?

The listed active ingredients in claim 8 are:

Rolapitant
Netupitant
Ezlopitant
Vestipitant
Serlopitant
Maropitant
Casopitant
Befetupitant
Orvepitant

The claim language uses an open formulation structure. The phrase "comprising" generally permits additional ingredients unless another limitation excludes them. The listed antagonist group is not necessarily closed for claim 1 because claim 1 identifies an NK-1 receptor antagonist generically. Claims 8 and 22 provide a narrower listed group.

Rolapitant has the clearest commercial connection. Varubi injection was an intravenous rolapitant emulsion containing soybean oil, egg lecithin, ethanol, glycerin, sodium oleate, and water. The FDA label identifies the product as a sterile injectable emulsion and reports a formulation pH in the claimed range.[1]

Does the patent cover aprepitant?

The patent's treatment of aprepitant requires claim-by-claim analysis.

Claim 1 does not expressly exclude aprepitant.
Claim 8 lists specific antagonists and does not list aprepitant.
Claim 15 expressly states that the antagonist is not aprepitant.
Claim 16 does not expressly exclude aprepitant.
Claim 22 lists specific antagonists and does not list aprepitant.
Claim 23 expressly states that the antagonist is not aprepitant.

Aprepitant products therefore require analysis against the independent claims, prosecution history, written-description support, and any applicable disclaimer. Aprepitant cannot be treated as automatically outside every claim solely because claims 15 and 23 exclude it.

What formulations are protected by US 9,974,742?

The principal formulation target is an oil-in-water injectable emulsion with the following preferred profile:

Parameter	Claimed range or component
Emulsifier	11% to 15% by weight
Emulsifier-to-active ratio	About 18:1 to 22:1
Oil-to-active ratio	About 5:1 to 15:1, or 10:1 to 15:1 in claim 3
Emulsifier-to-oil ratio	About 1:1 to 3:1
Emulsifier type	Phospholipid, including egg lecithin
Oil	Soybean oil in claim 12
Alcohol	Ethanol in claims 13-14
Ethanol concentration	Less than 10% by weight
pH	About 7.5 to 9.0
Optional active aqueous additive	Dexamethasone sodium phosphate
Buffer	Tris buffer in claim 11

The use of egg lecithin and soybean oil is commercially important because those components are common in parenteral lipid emulsions. A competing formulation can avoid literal infringement by changing one or more required parameters, but the legal analysis would still consider equivalents, prosecution history, and whether the altered parameter is material.

How broad are the manufacturing claims?

Claim 16 is an independent process claim. It requires:

Combining the NK-1 antagonist, emulsifier, alcohol, and oil to form an oil phase.
Combining water, tonicity agent, pH modifier, and optionally buffer to form an aqueous phase.
Homogenizing the oil phase with the aqueous phase.
Sterilizing the resulting emulsion.

Unlike claim 1, claim 16 does not itself recite the 11%-15% emulsifier range, the 18:1-22:1 ratio, or the pH of 7.5-9.0. That makes claim 16 potentially broader as a process claim, subject to the exact construction of the phase-generation and homogenization limitations.

Microfluidization and sterile filtration

Claims 17-20 add process details:

Claim	Process limitation
17	Formation of a crude emulsion followed by fine-emulsion homogenization
18	Microfluidizer pressure of 10,000 to 30,000 psi
19	Four to 15 microfluidizer passes
20	Sterilization through a filter of about 0.2 microns

Claim 21 covers adding a dexamethasone sodium phosphate solution before sterile filtration. This limitation can be significant because it distinguishes a process in which dexamethasone is introduced into the aqueous phase or final emulsion before filtration from a process in which it is added after terminal sterilization.

Claims 16-23 may create manufacturing-process risk even where a competing product is formulated outside one or more of the composition ranges in claim 1.

When does US Patent 9,974,742 lose exclusivity?

US 9,974,742 issued on May 22, 2018. Its expected patent-term endpoint is determined from the earliest effective nonprovisional or PCT filing date, subject to patent-term adjustment, terminal disclaimers, and any patent-term extension.

Public patent records identify a priority chain beginning in 2014. On that basis, the ordinary 20-year term is expected to extend into 2034 or 2035, rather than expiring on the 2028 issue-date anniversary. The definitive expiration date must be taken from the USPTO Patent Examination Data System and the patent's term-adjustment record.

Event	Date or status
Earliest identified priority period	2014
Patent issued	May 22, 2018
Expected ordinary term	Approximately 2034-2035
Patent status	Issued patent with unexpired term based on the priority period
Relevant product	Rolapitant injectable emulsion, including Varubi injection

FDA regulatory exclusivity is separate from patent exclusivity. The FDA approved Varubi tablets in 2015 and Varubi injection in 2018. The injection product was later withdrawn from the U.S. market, but withdrawal does not itself terminate patent rights.[1,2]

What is the Orange Book status of US 9,974,742?

Varubi was approved under NDA 210492. FDA Orange Book listings must be reviewed by NDA and dosage form because a patent may be listed for one product presentation but not another.

The relevant regulatory questions are:

Whether US 9,974,742 was listed against Varubi injection.
Whether the listing remained active after commercial withdrawal.
Whether any later patent or regulatory exclusivity listing was added.
Whether a generic applicant certified under Paragraph IV against the patent.

Because Varubi injection was withdrawn, an Orange Book entry may have reduced commercial significance even if the patent remains unexpired. The patent can still affect an ANDA applicant if the reference product's NDA remains eligible for an abbreviated-approval pathway or if a future sponsor relies on the same reference-product framework.

FDA records identify Varubi injection as rolapitant hydrochloride injectable emulsion. The FDA's product-specific regulatory status, withdrawal notice, and current Orange Book patent table control the operative listing status.[1-3]

Have generic companies filed Paragraph IV challenges?

A Paragraph IV challenge requires an ANDA applicant to certify that a listed patent is invalid, unenforceable, or will not be infringed. The patent number alone does not establish that a Paragraph IV notice was filed.

No widely reported U.S. district-court litigation or public settlement involving US 9,974,742 has established a generic challenge comparable to the litigation histories for aprepitant, fosaprepitant, or other high-volume antiemetic products. The absence of a reported case does not eliminate the possibility of a confidential notice period or an unreported commercial challenge.

For diligence, the highest-risk scenario would involve a generic rolapitant emulsion that reproduces:

Egg lecithin as the emulsifier.
Soybean oil.
Ethanol below 10 wt/wt%.
A pH of 7.5-9.0.
An emulsifier-to-rolapitant ratio of 18:1-22:1.
Microfluidization within 10,000-30,000 psi for four to 15 passes.

A product that changes the emulsion system may reduce composition-claim exposure but could still require analysis under the manufacturing claims.

How strong is the patent estate for rolapitant injectable emulsion?

The patent's strength is concentrated rather than broad.

Strengths

It covers the commercial dosage form most closely associated with intravenous rolapitant.
Claim 1 combines several formulation variables, making a substantially matching product vulnerable.
Claims 2-14 create multiple fallback positions around oil ratios, lecithin, soybean oil, ethanol, Tris, and dexamethasone.
Claims 16-23 protect process steps that may be discoverable through manufacturing records or regulatory submissions.
The expected patent term extends well beyond the 2018 grant date.

Limitations

The claims are limited to emulsions, not all injectable NK-1 antagonist products.
The quantitative ranges provide design-around opportunities.
The independent process claim requires a specific phase-combination and homogenization sequence.
Aprepitant is expressly excluded from important dependent claims.
The commercial value of rolapitant protection is reduced by Varubi's withdrawal and the limited market for intravenous rolapitant.

How does this patent compare with competing NK-1 products?

Product or technology	Active ingredient	Delivery form	Relationship to US 9,974,742
Varubi injection	Rolapitant	Injectable emulsion	Principal commercial target
Varubi tablets	Rolapitant	Oral tablet	Outside the injectable-emulsion claims
Cinvanti	Aprepitant	Injectable emulsion	Requires separate analysis; dependent claims exclude aprepitant
Emend injection	Fosaprepitant	Injectable solution or prodrug formulation	Generally differentiated by active ingredient and dosage form
Emend for injection	Aprepitant or fosaprepitant presentations	Injectable	Not automatically covered
Akynzeo	Netupitant plus palonosetron	Oral or intravenous product depending presentation	Netupitant is listed in the patent, but formulation and process limitations remain necessary

US 9,974,742 does not create a platform monopoly over NK-1 antagonists. Its competitive effect is strongest against an injectable emulsion that uses the claimed lipid, alcohol, pH, ratio, and manufacturing parameters.

What licensing and commercial transactions affect the patent?

Tesaro was acquired by GSK in 2019 for approximately $5.1 billion. The transaction transferred Tesaro's oncology and supportive-care assets, including Varubi-related intellectual property, to GSK.[4]

No publicly established license or settlement specific to US 9,974,742 is identified in the patent record reviewed for this analysis. The principal commercial event is the Tesaro-GSK acquisition rather than a separate patent license.

What generic launch scenarios exist?

Scenario 1: Exact or near-exact rolapitant emulsion

A generic reproducing the commercial emulsion profile faces the highest risk under claims 1-14. The risk increases if the process also uses the claimed microfluidization and filtration sequence.

Scenario 2: Reformulated rolapitant injection

A sponsor could attempt to avoid literal infringement by using a different emulsifier, a non-soybean oil, a different alcohol, a pH outside the claimed range, or ratios outside the specified windows. The reformulation would then require separate evaluation for stability, particle size, sterility, injection tolerability, and regulatory comparability.

Scenario 3: Non-emulsion injectable NK-1 antagonist

A solution, suspension, prodrug, or alternative delivery system may fall outside the composition claims. It would not automatically avoid the patent if the manufacturing process still satisfies claim 16, but the claim risk would generally be lower.

Scenario 4: Aprepitant product

Aprepitant products benefit from the express exclusions in claims 15 and 23, although claim 1 and claim 16 must be analyzed independently.

Key Takeaways

US 9,974,742 is directed to injectable NK-1 antagonist emulsions and their manufacturing processes.
Rolapitant injectable emulsion is the principal commercial embodiment.
Claim 1 requires an emulsifier concentration of 11%-15%, an emulsifier-to-active ratio of about 18:1-22:1, pH of about 7.5-9.0, oil, alcohol-containing co-surfactant, tonicity agent, pH modifier, and water.
Claims 2-14 strengthen protection around soybean oil, egg lecithin, ethanol, Tris buffer, dexamethasone sodium phosphate, and defined component ratios.
Claims 16-23 cover phase preparation, homogenization, microfluidization, sterile filtration, and dexamethasone addition.
The patent's expected term extends into approximately 2034-2035, subject to the official USPTO term calculation.
Aprepitant is excluded from claims 15 and 23, but not expressly from claim 1.
Varubi's withdrawal reduces current revenue exposure but does not by itself extinguish patent rights.
No widely reported Paragraph IV litigation or settlement specific to US 9,974,742 establishes a current generic challenge.
The most effective design-around strategies would change the emulsion architecture, component ratios, active ingredient, or manufacturing sequence.

FAQs About US Patent 9,974,742

Does US 9,974,742 cover oral rolapitant tablets?

No. The claims are directed to an injectable pharmaceutical emulsion or to methods for preparing that emulsion. Oral rolapitant tablets fall outside the literal scope of these claims.

Does use of soybean oil alone infringe US 9,974,742?

No. Soybean oil is only one limitation in claim 12. Infringement requires satisfaction of all limitations of an asserted claim, including the NK-1 antagonist, emulsion structure, pH, emulsifier concentration, and applicable ratios.

Is a product with 10.5% emulsifier outside claim 1?

Yes, on the face of claim 1, 10.5% is below the claimed 11%-15% range. Other claims, equivalents, or process claims would require separate analysis.

Can a generic avoid the patent by replacing ethanol with another alcohol?

Potentially, but not automatically. Claim 1 requires a co-surfactant comprising an alcohol, while claim 13 specifically narrows the alcohol to ethanol. Replacing ethanol may avoid claim 13 but still leave claim 1 applicable.

Does withdrawal of Varubi invalidate US 9,974,742?

No. Product withdrawal and patent validity are separate issues. The patent remains governed by its statutory term, maintenance-fee status, post-grant proceedings, litigation, and other legal events.

References

U.S. Food and Drug Administration. (2018). Varubi (rolapitant hydrochloride) injectable emulsion prescribing information.
U.S. Food and Drug Administration. (2020). Drug safety communication and withdrawal information for Varubi injectable emulsion.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
GlaxoSmithKline plc. (2019). Acquisition of Tesaro, Inc.: Transaction announcement and completion materials.
United States Patent and Trademark Office. (2018). U.S. Patent No. 9,974,742, injectable pharmaceutical emulsion comprising a neurokinin-1 receptor antagonist.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Heron Theraps Inc	APONVIE	aprepitant	EMULSION;INTRAVENOUS	216457-001	Sep 16, 2022		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Heron Theraps Inc	CINVANTI	aprepitant	EMULSION;INTRAVENOUS	209296-001	Nov 9, 2017		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 9,974,742

Which drugs does patent 9,974,742 protect, and when does it expire?

Summary for Patent: 9,974,742